323 related articles for article (PubMed ID: 28460011)
1. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
4. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells.
Chen YC; He XL; Qi L; Shi W; Yuan LW; Huang MY; Xu YL; Chen X; Gu L; Zhang LL; Lu JJ
Biochem Pharmacol; 2022 Mar; 197():114940. PubMed ID: 35120895
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
6. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
8. HPV prevalence and p16INKa overexpression in non-smoking non-drinking oral cavity cancer patients.
Dediol E; Sabol I; Virag M; Grce M; Muller D; Manojlović S
Oral Dis; 2016 Sep; 22(6):517-22. PubMed ID: 26993152
[TBL] [Abstract][Full Text] [Related]
9. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
Jiang C; Yuan F; Wang J; Wu L
Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495
[TBL] [Abstract][Full Text] [Related]
10. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
[TBL] [Abstract][Full Text] [Related]
12. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
Lenouvel D; González-Moles MÁ; Ruiz-Ávila I; Gonzalez-Ruiz L; Gonzalez-Ruiz I; Ramos-García P
Oral Oncol; 2020 Jul; 106():104722. PubMed ID: 32330687
[TBL] [Abstract][Full Text] [Related]
14. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
[TBL] [Abstract][Full Text] [Related]
16. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
Gao A; Pan X; Yang X; Lin Z
Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
[TBL] [Abstract][Full Text] [Related]
19. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
[TBL] [Abstract][Full Text] [Related]
20. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.
Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
APMIS; 2018 Sep; 126(9):732-738. PubMed ID: 30160018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
